[Clinical development of S-1 (TS-1) for advanced gastric cancer].
The 5-FU plus cisplatin containing regimen like FP, ECF and DCF, is considered to be the most effective treatment for advanced gastric cancer in the United States, Europe, and Korea. In Japan, oral fluoropyrimidine S-1 (TS-1) is currently considered to be the first candidate as the standard drug for advanced gastric cancer. S-1 based combination therapies with other promising drugs like cisplatin, irinotecan and taxanes, are expected to yield good results. Above all, S-1+CDDP therapy showed a high efficacy and expected to be a standard therapy for advanced gastric cancer. Two large phase III studies, JCOG 9912 5-FU vs S-1 vs CPT-11 +CDDP and S-1 vs S-1+CDDP, are now on going to establish an acceptable frontline standard for patients with AGC. We therefore need to develop new agents and combination chemotherapy regimens to achieve a greater survival benefit in AGC.
Wasaburo
Koizumi
K
Dept. of Gastroenterology and G I Oncology, Kitasato University School of Medicine, Sagamihara, Japan.
Tanabe
Satoshi
S
Higuchi
Katsuhiko
K
Sasaki
Toru
T
Nakayama
Norisuke
N
Mihara
Shizuka
S
Nakatani
Kento
K
Nishimura
Ken
K
Shimoda
Takuya
T
Azuma
Mizutomo
M
Katada
Chikatoshi
C
Hanaoka
Noboru
N
Naruke
Akira
A
Ryu
Takahiro
T
Ishido
Kenji
K
Saigenji
Katsunori
K
D000284:Administration, Oral; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004334:Drug Administration Schedule; D004338:Drug Combinations; D006801:Humans; D010094:Oxonic Acid / Q000008:administration & dosage*; D017410:Practice Guidelines as Topic; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage*
D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002945:Cisplatin